USPTO serial 79445549
STRATIFAI
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- INNES, ISABEL J
- Law office
- TMO LAW OFFICE 135
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with STRATIFAI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable software using artificial intelligence for use in the fields of healthcare, biotechnology, and life sciences; downloadable software using artificial intelligence for analysis of clinical data including histopathology, radiology, genomic, and multi-omics data; downloadable software using artificial intelligence and machine learning for use with predictive biomarker discovery tools to discover, identify and validate biomarkers; downloadable software relating to clinical decision support to assist healthcare professionals by offering targeted clinical knowledge, patient information, and other relevant data to support clinical decision-making; downloadable software for diagnostic purposes to provide solutions for pharmaceutical and biotech companies to support targeted therapies; downloadable software to optimise drug development and clinical trials including patient recruitment and response prediction; downloadable software for processing clinical research, diagnostic support and treatment optimisation in oncology and complex diseases; downloadable artificial intelligence software for clinical data analysis and medical diagnostics. | ACTIVE | — |
| 042 | Design and development of software featuring artificial intelligence for use in the fields of healthcare, biotechnology, and life sciences; providing temporary use of non-downloadable software using artificial intelligence for analysis of clinical data including histopathology, radiology, genomic, and multi-omics data; software as a service (SaaS) featuring artificial intelligence software for use in drug research and development, clinical trials, biomarker research and development, diagnostic testing, clinical testing, and clinical diagnostics; research and development of software relating to biomarker discovery, identification and validation tools; research and development of software relating to diagnostic testing, clinical testing and clinical diagnostics; clinical and scientific research using artificial intelligence in the field of digital pathology namely providing digital oncology solutions; providing temporary use of non-downloadable software for processing clinical research, diagnostic support and treatment optimisation in oncology and complex diseases; providing temporary use of non-downloadable software for clinical decision support to assist healthcare professionals in personalised treatment planning; providing temporary use of non-downloadable software for diagnostic purposes to provide solutions for pharmaceutical and biotech companies to support targeted therapies; providing temporary use of non-downloadable software to optimise drug development and clinical trials including patient recruitment and response prediction; providing temporary use of non-downloadable software for medical image processing and analysis; platform as a service (PaaS) featuring platforms for clinical data analysis, integrated clinical research platforms, diagnostic support systems in oncology, treatment optimization for complex diseases; providing online non-downloadable computer software platforms for scientific research and clinical diagnostics; cloud-based software services and proprietary software as software as a service [SaaS] for clinical data analysis and medical diagnostics accessible to hospitals, diagnostic laboratories, research institutions, and pharmaceutical companies; consultancy and advisory services relating to all of the aforesaid. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 16, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 26, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 26, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 8, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 7, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 3, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 13, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 13, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 12, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |